April 15, 2024
Growth surpasses the previous year's 6.18% increase
Exports to the US reached US$ 7.83 billion in the April-February period.
Overall, pharmaceutical exports from India rose by 9.34%
The US market constitutes 30% of India's total pharmaceutical exports
Following a period of stagnation, India’s pharmaceutical exports to the US have surged by 15% in the first 11 months of the previous financial year despite facing regulatory hurdles and increasing pricing pressures. According to estimates provided by the Pharmaceutical Export Promotion Council (Pharmexcil), the export growth rate has more than doubled compared to the 6.18% increase in the fiscal year 2022-23.
During the April-February timeframe, exports to the US escalated from US$ 6.8 billion to US$ 7.83 billion, marking a significant rise. Meanwhile, India’s overall pharmaceutical exports saw a 9.34% increase, totalling US$ 25.04 billion compared to US$ 22.9 billion in the same period.
The US market constitutes approximately 30% of India’s total pharmaceutical exports. R Uday Bhaskar, Director General of Pharmexcil, expressed optimism about the rebound in exports to the US, considering the prior negative growth observed in 2022. He highlighted that until fiscal year 2016, India consistently experienced export growth rates exceeding twice the norm, attributed to expedited approvals of Abbreviated New Drug Applications (ANDAs). However, Bhaskar noted a subsequent deceleration in the approval rate by the US Food and Drug Administration (USFDA), coupled with sluggishness in the US domestic market.
Source: Economic Times